OpenAI acquired Orchestra Bio, a four-year-old AI biotech software startup, on Tuesday, according to the company's website. The terms of the deal were not disclosed. Orchestra Bio had raised about $20 million by 2025 from investors including Andreessen Horowitz, Atria, and 8VC. The startup develops AI agents that assist biotech firms in managing drug discovery operations, such as tracking finances and scheduling clinical trials.
The acquisition will integrate Orchestra Bio's team and technology into OpenAI's Rosalind project, an AI model focused on life sciences research. OpenAI plans to enhance Rosalind and its related Rosalind Workbench tool, which helps researchers design experiments and analyze data. OpenAI has secured major customers for Rosalind, including Moderna and Novo Nordisk, highlighting the model's growing adoption in the pharmaceutical sector.
This move reflects a broader trend where leading AI labs like OpenAI and Anthropic are expanding their software offerings to serve large industries such as pharmaceuticals. Instead of competing directly with startups, OpenAI is absorbing Orchestra Bio to strengthen its position in biotech AI. The deal underscores the increasing convergence of AI technology with drug discovery and life sciences research, a sector attracting significant AI investment.
Orchestra Bio had raised $20 million as of 2025, with backing from prominent venture firms. OpenAI’s acquisition was announced on Tuesday via its website, marking a strategic step in scaling its Rosalind AI model for life sciences applications.